1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Regulation

Naloxone Still On US House Appropriators’ Radar, But OTC Access Remains Off Screen

FDA FY2022 Budget Report Comments On Switches, Acetaminophen Labeling, Homeopathics

 
• By Malcolm Spicer

Committee report again includes item concerning FDA’s work on expanding access to opioid antagonist naloxone. It still doesn’t acknowledge agency’s interest in making drug available OTC in a nasal inhaler, but emphasizes access for pregnant and postpartum women.

House appropriators’ changes in their comments on the US Food and Drug Administration’s work on expanding access to the opioid overdose remedy naloxone miss the point about making it available nonprescription as the agency has emphasized.

The Appropriation Committee’s report published with legislation for the FDA’s fiscal year 2022 funding along with budgets for the Department...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

FDA Takes World Tour In Recent OTC Warnings

 
• By Malcolm Spicer

FDA Center for Drug Evaluation and Research Office of Manufacturing Quality, Office of Compliance and Office of Unapproved Drugs & Labeling Compliance recently advise Indian, Canadian and US firms about GMP problems.

German Associations Call For EU Green Claims Directive Trilogue Suspension

 
• By David Ridley

Pharma Deutschland is one of 21 German associations calling for trilogue negotiations in relation to the EU Green Claims Directive to be suspended while a “comprehensive and independent written impact assessment” is undertaken.

Over The Counter: EU Omnibus And ESG, What You Need To Know, With CEN Group’s Jasper Crone

 
• By David Ridley

HBW Insight catches up with sustainability expert Jasper Crone to find out what consumer health companies need to know about the European Commission's Omnibus simplification package.